Skip to content Skip to Search
Skip navigation

Saudi’s Avalon plans massive export drive

Saudi Arabia wants to localise the production of more pharmaceutical products and at the same time expand sales to global markets Unsplash/Glsun Mall
Saudi Arabia wants to localise the production of more pharmaceutical products and at the same time expand sales to global markets
  • Avalon Pharma aims to treble revenue
  • Push to raise exports to 30%
  • More local production planned

The Saudi pharmaceuticals firm Avalon Pharma plans to treble revenue to SAR1.1 billion ($290 million), with a drive to increase exports from 10 percent to 30 percent of output.

As Saudi Arabia pushes to produce within its own borders more of the medicines it consumes, Maher Al Ghannam, managing director and CEO of Avalon Pharma, said his firm will open a SAR100 million factory by 2026, its fourth.

“We want to localise more pharmaceutical products in Saudi Arabia and expand to global markets,” he said. 

“We have a wide portfolio of generic medications, pharmaceutical products that were developed, manufactured and distributed in Saudi Arabia.” 

The country’s pharma sector is currently valued at SAR38 billion, a figure that is set to increase to SAR70 billion by 2030, the deadline that Saudi Arabia has been working towards in its vast plan to diversify its economy away from oil. 

Multinationals such as Pfizer and Johnson & Johnson still dominate the market. However, their share is falling with the rise of around a dozen Saudi companies, helped by regulatory reforms and a trend for foreign pharmaceutical giants to partner with companies for local manufacture of their products. 

Al Ghannam said Avalon, which is not listed on the Saudi stock exchange, is the fourth largest pharmaceutical in the kingdom. He said the company was working closely with the Saudi Export Development Authority, using the “Made in Saudi” logo. 

There are 40 pharmaceutical factories in Saudi Arabia, covering close to 30 percent of the country’s needs.  

Al Ghannam listed three future product growth areas: obesity, oncology and cardio-metabolic medicines. He said his company was committed to research and development. 

Avalon Pharma, which began in 1998, is the leader in Saudi dermatology products. 

The company’s growth was part of a broader national strategy, Al Ghannam said. Avalon will continue to invest “millions of riyals to enhance its presence in the sector and contribute to the development of medical industries in the kingdom,” he said. 

Latest articles

Gulf bank rates

Gulf banks face margin squeeze as funding costs rise

Gulf banks are likely to offer more attractive rates on savings accounts to woo depositors, putting more pressure on lenders’ already tight net interest margins, a report suggests. The move towards higher interest rates for savers is predicted to become more pronounced as expectations of imminent rate cuts by the US Federal Reserve fade. Benchmark interest […]

Mubadala Investment Company CEO Khaldoon Khalifa Al Mubarak. The Abu Dhabi wealth fund is selling some GlobalFoundaries shares two years after the US company went public

Mubadala trims stake in US chipmaker GlobalFoundries

Abu Dhabi sovereign wealth fund Mubadala Investment Company is offloading some of its holdings in chipmaker GlobalFoundries.  A Mubadala subsidiary is offering to sell $950 million worth of GlobalFoundries shares, two years after the US semiconductor manufacturer went public on Nasdaq. Mubadala Technology Investment Company will receive the funds from the secondary public offering, which […]

Saudi arabia water

$4bn set aside for Saudi water projects

Saudi Arabia will spend $4 billion by the end of the decade on recycling over 2 billion cubic metres of water, about 70 percent of the country’s renewable water sources, an official said this week.  Speaking at the World Water Forum in Indonesia, Mohammed bin Zaid Abuhid, head of the General Authority for Irrigation, outlined […]

Cigarette sellers in Aswan, Egypt. US company Philip Morris says it wants to give smokers in Egypt 'better options than cigarettes'

US cigarette giant buys slice of Egyptian rival

The American tobacco giant Philip Morris International (PMI) has acquired a minority stake in Egypt’s largest cigarette manufacturer. PMI, which owns brands such as Marlboro, L&M, Merit and Parliament and is the world’s top tobacco company by market value, has bought 14.7 percent of Egypt’s Eastern Company, which also includes cigars and pipe tobacco in […]